Bing Yao

Dr. Bing Yao is the Chief Executive Officer and Chairman of ArriVent BioPharma. Dr. Yao is an accomplished executive and scientist with more than 25 years of experience in the biotechnology and pharmaceutical industry. Most recently, he served as Chairman and CEO of Viela Bio, which he co-founded in 2018. In 2021, Viela Bio was acquired by Horizon Therapeutics for $3 billion. Prior to his role at Viela, he served as Senior Vice President, R&D and Head of Respiratory, Inflammation & Autoimmunity at MedImmune and as Senior Vice President, Head of Immuno-Oncology Franchise at AstraZeneca. During his tenure at MedImmune and AstraZenca, he played key leadership roles in the development and approval of multiple novel biologics for autoimmune, respiratory, and immune-oncology indications respectively. Prior to joining MedImmune, Dr. Yao led the project team leaders group for immunology, neurosciences, virology and metabolism for Genentech, and prior to that, served as Vice President of Research and Corporate Officer for Tanox before it was acquired by Genentech. Earlier in his career Dr. Yao held key roles at Aventis and Amgen. Dr. Yao has authored more than 50 peer-reviewed publications and holds over 20 patents and patent applications.